What is PurMabiologics?
PurMabiologics operates as a specialized provider of high-quality, cost-effective reagents and cell culture media, serving as a critical infrastructure partner for the pharmaceutical and biotechnology sectors. The company maintains a robust portfolio that includes essential buffers, serums, and advanced mycoplasma detection and elimination reagents. Beyond its product offerings, PurMabiologics distinguishes itself through specialized technical services, including monoclonal antibody production, protein expression, and biochemical conjugation. This dual-model approach allows the firm to support complex research and development workflows, ensuring that clients can maintain rigorous standards in their own laboratory environments while optimizing production efficiency.
How much funding has PurMabiologics raised?
PurMabiologics has raised a total of $13K across 1 funding round:
Debt
$13K
Debt (2021): $13K with participation from PPP
Key Investors in PurMabiologics
PPP
Public-Private Partnership
What's next for PurMabiologics?
With the recent influx of capital, PurMabiologics is poised to transition into a more aggressive growth phase. The strategic roadmap likely involves scaling its manufacturing capacity to meet the rising demand for specialized cell culture solutions and enhancing its R&D pipeline to introduce next-generation reagents. As the company navigates the Series A/B growth stage, management will likely prioritize market penetration and the strengthening of its service-based revenue streams. By focusing on operational excellence and innovation, PurMabiologics aims to solidify its reputation as a reliable partner for global biotech firms, ultimately driving long-term value for stakeholders and advancing the broader life sciences ecosystem.
See full PurMabiologics company page
